Dia.Pro Diagnostic Bioprobes s.r.l products
COVID-19 - CLIA
DIA.CHEMILUX - SARS-CoV-2 NCP IgG – CLIA
Chemi-Luminescence ImmunoAssay (CLIA) for the semi-quantitative determination of IgG antibodies to SARS-CoV-2 Nucleocapsid protein (NCP) in human plasma and sera. The kit is intended for monitoring of infected patients. In addition the kit may be used when testing the population and health-care workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase of infection, in combination with SARS-COV-2 molecular tests. The device has been adapted for the use in exclusive combination with the Dia.Pro CLIA random access instrument named SARA.
DIA.CHEMILUX - SARS-CoV-2 ACE2/RBD Neutralization – CLIA
Chemi-Luminescence ImmunoAssay (CLIA) for the serological determination of the neutralization activity of antibodies to SARS-CoV-2, induced by natural infection and/or vaccination, able to block the interaction of Receptor Binding Domain (RBD) and ACE2 and thus the virus infection.
DIA.CHEMILUX - SARS-CoV-2 Spike/RBD Ab – CLIA
Chemi-Luminescence ImmunoAssay (CLIA) for the quantitative determination of antibodies to COVID-19 Virus (SARS-CoV-2) Spike/RBD in human plasma and sera.
COVID-19 - ELISA
COVID-19 IgG/IgM Confirmation and Typing – ELISA
Module-based Enzyme-Immuno-Assay (ELISA) for the confirmation of samples positive for IgG and IgM antibodies to COVID-19 in first screening. The test is particularly useful in monitoring patients, infected by COVID-19, from the time of symptoms offset up to full recovery. The test can be used in addition to identify (a) the specificity (“typing”) of antibodies to the major immunodominant COVID-19 antigens and (b) identify those samples with a titer of “potentially” neutralizing IgG to Spike antigens such to select the donor as a candidate for immunotherapy, as well.
COVID-19 Spike 1&2 IgG – ELISA
Enzyme ImmunoAssay (ELISA) for the semi-quantitative determination of IgG antibodies to COVID-19 Spike antigens in human plasma and sera. The IgG assay is intended for testing: (a) health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing anti Spike IgG; (b) normal population for epidemiology studies on presence of potential “protective” IgG to COVID-19 Spike antigens; (c) PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies; (d) human donors, recovered from COVID-19 infection, positive for anti-Spike IgG for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease; (e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike IgG antibodies.